Journal editors question sale of diet pill Meridia

Sep 01, 2010 By STEPHANIE NANO , Associated Press Writer

(AP) -- Editors of a top medical journal are questioning whether the diet pill Meridia should stay on the market even if it's restricted to people without heart disease.

A new study shows the appetite suppressant raises the risk of and stroke in people with heart problems.

The strongly worded editorial in Thursday's comes two weeks before government advisers review the prescription drug.

The weight-loss pill has already been pulled in Europe and U.S. drug regulators have added stronger warnings to the label.

The maker of the diet pill, Abbott Laboratories, says it's still appropriate for obese people who don't have and who can't lose weight through diet and exercise.

Explore further: Express Scripts turns to AbbVie in huge hepatitis C deal

2 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

Experimental diet pill shows promise, little risk

Jul 14, 2010

(AP) -- An experimental diet pill helped about half the people who tried it lose some weight and keep it off a year later, without the heart problems that some earlier drugs caused, a study found.

Health Canada warns against Meridia

Oct 16, 2007

Health Canada issued a warning for doctors not to prescribe the weight loss drug Meridia to people who may be at risk of serious heart-related side effects.

FDA to review first of 3 new weight loss drugs

Jul 12, 2010

(AP) -- Dieters, doctors and investors get their first extensive look at the first of a trio of new weight loss drugs this week. The hope is that the new drugs can succeed where many others have failed: delivering significant ...

FDA panel rejects experimental weight loss pill

Jul 15, 2010

(AP) -- A panel of federal health experts dealt a surprising setback Thursday to a highly anticipated anti-obesity pill from Vivus Inc., saying the drug's side effects outweigh its ability to help patients lose weight.

Pill claims weight loss with no diet

Oct 08, 2007

Akavar 20/50, a pill produced in Salt Lake City, has become the most recent product to advertise weight loss with no diet or exercise.

Recommended for you

Express Scripts turns to AbbVie in huge hepatitis C deal

5 hours ago

The nation's largest pharmacy benefits manager is throwing its weight into a fight over the high cost of treating hepatitis C, saying it will cover a new drug from AbbVie while pulling back on more expensive ...

FDA OKs Cubist antibiotic for serious infections

Dec 20, 2014

The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May.

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

Dec 18, 2014

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.